FLAG with Bortezomib in Childhood Relapsed Refractory Leukaemia- A
Single Centre Experience
Abstract
Relapsed refractory leukaemia represents a difficult to treat population
of patients. The balance between perceived benefit and potential side
effects along with the significant financial burden of managing
multidrug resistant sepsis are factors which determine the choice of
salvage regimen. Here we present our experience with the combination of
Fludrabine, Cytarabine, GCSF with Bortezomib. The morphological complete
response rate was 58.% with 50% of the patients achieving complete
remission. With only three patients requiring ICU admission during the
period of care. 66.6% of the patients went on to undergo successful
hematopoietic stem cell transplantation. Thus, proving to be a possible,
safer alternative to other salvage regimens